Patrick O. Brown

Last updated
Patrick O. Brown
Patrick O Brown.jpg
Photo by Jane Gitschier
Born
Patrick O'Reilly Brown

1954 (age 69–70)
Washington, D.C., U.S.
Other namesPat
Alma mater The University of Chicago
Known for Impossible Foods, DNA microarrays [1] [2]
Public Library of Science
Awards NAS Award in Molecular Biology (2000)
Takeda award (2002)
Curt Stern Award (2005)
Scientific career
Fields Biochemistry
Institutions Stanford University
Thesis Studies on DNA Topoisomerases  (1980)
Doctoral advisor Nicholas Cozzarelli
Doctoral students Kathleen Rubins
Joseph DeRisi
Website brownlab.stanford.edu
www.hhmi.org/research/investigators/brown_bio.html

Patrick O'Reilly Brown (born 1954) is an American scientist and businessman who is the founder of Impossible Foods Inc. [3] and professor emeritus in the department of biochemistry at Stanford University. [4] Brown is co-founder of the Public Library of Science, [5] inventor of the DNA microarray, [6] and a former investigator at Howard Hughes Medical Institute. [7]

Contents

Education

Brown received each of his degrees from The University of Chicago, including his B.S. in 1976 and M.D. in 1982. His Ph.D., granted in 1980 while under the guidance of Nicholas R. Cozzarelli, involved the study of DNA topoisomerases. [8]

Academic career

After getting his medical degree in 1982, Brown completed a 3-year pediatric residency at Children's Memorial Hospital in Chicago but decided he could have a greater impact through basic research. [9] In 1985, Brown took a 3-year postdoctoral fellowship at the University of California, San Francisco with J. Michael Bishop and Harold Varmus (who shared the 1989 Nobel Prize in Medicine for their discoveries about how genes can ignite cancerous tumors). [10] At UCSF, Brown and colleagues defined the mechanism by which retroviruses, such as the HIV virus, integrate their genes into the genome of the cells they infect, which helped lead to development of new drugs to fight the disease. [11]

In 1988, Brown became an investigator of the Howard Hughes Medical Institute and an assistant professor in the department of biochemistry at Stanford University School of Medicine, where he continued to investigate retroviral replication. [9] In the early 1990s, Brown began developing a new technology to enable systematic investigation of the behavior and properties of whole genomes—called DNA microarrays. [12] "I had a mental image of a DNA microarray, even including the red and green fluorescent spots, a few years before I'd figured out the details of making them," Brown told The Scientist. [13]

Brown and his colleagues created a robotic dispenser that could deposit minute quantities of tens of thousands of individual genes onto a single glass slide, a “DNA microarray” or "gene chip." By flooding the slide with fluorescently labeled genetic material derived from a living sample, a researcher could see which genes were being expressed in cells. [14] Shortly after their first description of DNA microarrays, the Brown laboratory published a “how-to” manual on the Web that helped these robotic devices become standard equipment in life science labs throughout the world, in an effort led by Joe DeRisi, Michael Eisen, Ash Alizadeh, and others. [11]

Brown and his colleagues developed experimental methods for using DNA microarrays to investigate basic principles of genome organization, gene expression, cell regulation and specialization, physiology, development and disease, and the microbiome, along with statistical and computational tools for visualizing and interpreting the resulting large volumes of data. This work was especially revealing for the molecular portraits of many human cancers including lymphomas such as DLBCL, breast cancers, and other tumors, as part of diverse global collaborations including David Botstein, Michael Eisen, Lou Staudt, Ash Alizadeh, and others. Microarray technologies are widely used for comparing gene expression patterns and other genome features among individuals and their tissues and cells, providing information on disease subcategories, disease prognosis, and treatment outcome. [15]

Starting in the late 1990s, Brown began publicly voicing concern over what he called "a fundamentally flawed process of scientific publishing," [11] in which academics typically published results of publicly funded research in private, commercial publishing houses that charged subscription fees for access to journals. “We viewed this entire process as being patently unfair. Not only were scientists in poor countries being denied access to the latest and best information out there, but the public who supports this research was being denied access as well. We felt there simply had to be a better way to do it," Brown told a University of Chicago medical journal. [11]

Brown began a collaboration with other scientists, including Harold Varmus (then director of the National Institutes of Health), David J. Lipman (then director of the National Center for Biotechnology Information), and Michael Eisen of Lawrence Berkeley National Laboratory, to overhaul the scientific and medical publishing systems to make papers available on the rapidly developing Internet platforms such as Usenet and the World Wide Web. [16] "Why should publishers be able to control what I can do with information that was published by my scientific colleagues whose motivation was exactly to have their discoveries contribute to future discoveries? ... We had already existing tools that we could use to so to speak hyperlink things so that you could reorganize information in systematic ways, but they weren't really being exploited by the conventional scientific literature," Brown said in an interview with BioMedCentral Biology. [17] The magazine Nature reported that the scientists' open-access movement could "spell the end for many print titles"; [18] Brown called subscription-based scientific journals "anachronisms." [14]

In 2001, Brown, Eisen and Varmus co-founded the Public Library of Science (PLOS) to make published scientific research open access and freely available to researchers in the scientific community. [19] Funded by a grant from the Gordon and Betty Moore Foundation, the non-profit organization advocated for designing alternative systems to fund for scientific publishing. [20]

In 2002, Brown was elected to the United States National Academy of Sciences, identifying him as one of the top 2000 scientists in the nation. He is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science. [21]

Impossible Foods

In 2009, Brown took an 18-month sabbatical where he considered how to spend the rest of his career. [22] Brown decided that the world's largest environmental problem, [23] and the problem where he could have the most impact, was the use of animals to produce food. [24] He organized a conference to raise awareness of the problem. [25] But the National Research Council workshop, called "The Role of Animal Agriculture in a Sustainable 21st Century Global Food System,” had minimal impact; soon after, he decided the best way to reduce animal agriculture was to offer a competing product in the free market. [22]

By the end of his sabbatical, Brown had articulated the first steps of his business plan and began to recruit a small team of scientists to determine precisely why meat smells, handles, cooks and tastes like meat. [22] Brown said he had a "hunch" that the key to meat's unique taste was its high abundance of heme, an iron-containing molecule in blood that carries oxygen and is found in all living organisms. [26] Brown theorized that, if he could generate large amounts of heme from plant sources, he could recreate the taste of animal meat. [27]

Brown and a small group of early employees tested the hunch by digging up clover roots, which for the plant kingdom contain high amounts of heme. "I dissected them off with a razor blade then blended them up just to see what I could extract. I was just poking around, feasibility-testing some ideas. I got to a point where, though I didn’t have much data, I had enough to go and talk to some venture-capital companies — of which there are a ridiculous number in Silicon Valley — and hit them for some money,” Brown told The Sunday Times . [28] Brown raised $9 million and founded Impossible Foods in July 2011. [29] Over eight years until 2019, the business had collected $396 million from investors like Bill Gates, Google Ventures and Li Ka-shing’s Horizons Ventures. [30]

Brown and his team then spent five years researching and developing the Impossible Burger, which launched in restaurants in 2016. [31] Impossible Foods is also working on plant-based pork, chicken, fish and dairy products made without any animals. [32]

The safety of soy leghemoglobin produced by genetically engineered yeast was questioned by the FDA in 2015. [33] However, in 2018 the FDA stated that it had “no questions” regarding the safety or regulatory compliance of Impossible Foods’ soy leghemoglobin, [34] [35] a decision which has since been upheld by the Ninth Circuit Court of Appeals. [36] [37]

Brown strongly supports labeling Impossible Foods’ products as “meat,” regardless of its source. In a 2018 interview with Quartz , he noted, “animals have just been the technology we have used up until now to produce meat... What consumers value about meat has nothing to do with how it’s made. They just live with the fact that it’s made from animals. If we’re producing a product that is delivering everything that is of value in meat for consumers, it’s filling that niche.” This assessment, according to Brown, appropriately categorizes meat by “what functional role it plays,” rather than its source of origin. [38] These statements have put Brown at odds with the meat industry, which by mid-2019 had successfully pressured state legislatures in Missouri [39] [40] and Arkansas [41] [42] to pass laws barring plant-based protein manufacturers such as Impossible Foods and competitor Beyond Meat from labeling their products as “meat.”

The United Nations Framework Convention on Climate Change strongly endorses Brown's venture and vision, saying that animal-based meat is a "problem" and that in order to "achieve the United Nations Sustainable Development Goals, the global food system must undergo transformative change... By replacing animal products, consumers have enormous power to spare land for biodiversity and carbon capture, halt greenhouse gas emissions at the source, and alleviate demand on fresh water needed for healthy ecosystems." [43] Research on meats and no-meat substitutes suggests that no-meat products offer substantial benefits over the production of beef, and to a lesser extent pork and chicken, in terms of greenhouse gas production, water and land use. [24]

Awards

In 2000, Brown received the National Academy of Sciences Award in Molecular Biology. [44]

In 2002 he received a Takeda award, recognizing his work in "the development of DNA microarrays with pre-synthesized DNA probes and the promotion of the technology by releasing the production methods on the Internet." [45]

In 2005 he received the Curt Stern Award for his contributions to the development and application of gene-based expression microarrays. [46]

In 2006 he received the American Cancer Society's Medal of Honor for Basic Research, acknowledging "his revolutionary development of low-cost, accessible automated microarrays, and his life-saving contributions to the field of functional genomics...which in turn has produced insights into critical genetic information for diseases such as leukemia, lymphoma, prostate cancer, and early stage breast cancer." [47]

In 2010 the Association of Biomolecular Resource Facilities (ABRF) selected Brown for the ABRF 2010 Award in recognition of Brown's pioneering work in the development of microarrays and the diverse applications of this technology in genetic research. [48] That year, he also was awarded the Award for Excellence in Molecular Diagnostics by the Association for Molecular Pathology. [49]

In 2016, Klaus Schwab and the World Economic Forum named Brown and his company a "Technology Pioneer" for their design, development and deployment of new technologies and innovations "poised to have a significant impact on business and society." [50] Their citation reads: "Impossible Foods is creating meat and dairy substitutes directly from plants. They aim to eliminate the destructive environmental impact of the global animal farming industry by inventing sustainable and scalable ways to produce delicious, nutritious and affordable meat and dairy foods. Their technology transforms nutrients from plant crops directly into foods that have the flavours and textures of meat and dairy products, with all of the nutritional value." [51]

In 2018, the United Nations Environment Programme named Impossible Foods and Beyond Meat joint winners of the Champions of the Earth Award, in the Science and Innovation category. Pat Brown and Ethan Brown were awarded the award for production of sustainable alternatives to beef meats. [52]

Related Research Articles

<span class="mw-page-title-main">Bioinformatics</span> Computational analysis of large, complex sets of biological data

Bioinformatics is an interdisciplinary field of science that develops methods and software tools for understanding biological data, especially when the data sets are large and complex. Bioinformatics uses biology, chemistry, physics, computer science, computer programming, information engineering, mathematics and statistics to analyze and interpret biological data. The subsequent process of analyzing and interpreting data is referred to as computational biology.

<span class="mw-page-title-main">Cell cycle</span> Series of events and stages that result in cell division

The cell cycle, or cell-division cycle, is the series of events that take place in a cell that causes it to divide into two daughter cells. These events include the duplication of its DNA and some of its organelles, and subsequently the partitioning of its cytoplasm, chromosomes and other components into two daughter cells in a process called cell division.

<span class="mw-page-title-main">Genetically modified organism</span> Organisms whose genetic material has been altered using genetic engineering methods

A genetically modified organism (GMO) is any organism whose genetic material has been altered using genetic engineering techniques. The exact definition of a genetically modified organism and what constitutes genetic engineering varies, with the most common being an organism altered in a way that "does not occur naturally by mating and/or natural recombination". A wide variety of organisms have been genetically modified (GM), including animals, plants, and microorganisms.

<span class="mw-page-title-main">Genetic engineering</span> Manipulation of an organisms genome

Genetic engineering, also called genetic modification or genetic manipulation, is the modification and manipulation of an organism's genes using technology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. New DNA is obtained by either isolating and copying the genetic material of interest using recombinant DNA methods or by artificially synthesising the DNA. A construct is usually created and used to insert this DNA into the host organism. The first recombinant DNA molecule was made by Paul Berg in 1972 by combining DNA from the monkey virus SV40 with the lambda virus. As well as inserting genes, the process can be used to remove, or "knock out", genes. The new DNA can be inserted randomly, or targeted to a specific part of the genome.

Molecular biology is a branch of biology that seeks to understand the molecular basis of biological activity in and between cells, including biomolecular synthesis, modification, mechanisms, and interactions.

<span class="mw-page-title-main">Oncogene</span> Gene that has the potential to cause cancer

An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.

<span class="mw-page-title-main">Leghemoglobin</span> Phytoglobin

Leghemoglobin is an oxygen-carrying phytoglobin found in the nitrogen-fixing root nodules of leguminous plants. It is produced by these plants in response to the roots being colonized by nitrogen-fixing bacteria, termed rhizobia, as part of the symbiotic interaction between plant and bacterium: roots not colonized by Rhizobium do not synthesise leghemoglobin. Leghemoglobin has close chemical and structural similarities to hemoglobin, and, like hemoglobin, is red in colour. It was originally thought that the heme prosthetic group for plant leghemoglobin was provided by the bacterial symbiont within symbiotic root nodules. However, subsequent work shows that the plant host strongly expresses heme biosynthesis genes within nodules, and that activation of those genes correlates with leghemoglobin gene expression in developing nodules.

<span class="mw-page-title-main">Microarray</span> Small-scale two-dimensional array of samples on a solid support

A microarray is a multiplex lab-on-a-chip. Its purpose is to simultaneously detect the expression of thousands of biological interactions. It is a two-dimensional array on a solid substrate—usually a glass slide or silicon thin-film cell—that assays (tests) large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods. The concept and methodology of microarrays was first introduced and illustrated in antibody microarrays by Tse Wen Chang in 1983 in a scientific publication and a series of patents. The "gene chip" industry started to grow significantly after the 1995 Science Magazine article by the Ron Davis and Pat Brown labs at Stanford University. With the establishment of companies, such as Affymetrix, Agilent, Applied Microarrays, Arrayjet, Illumina, and others, the technology of DNA microarrays has become the most sophisticated and the most widely used, while the use of protein, peptide and carbohydrate microarrays is expanding.

<span class="mw-page-title-main">Genetically modified food</span> Foods produced from organisms that have had changes introduced into their DNA

Genetically modified foods, also known as genetically engineered foods, or bioengineered foods are foods produced from organisms that have had changes introduced into their DNA using various methods of genetic engineering. Genetic engineering techniques allow for the introduction of new traits as well as greater control over traits when compared to previous methods, such as selective breeding and mutation breeding.

<span class="mw-page-title-main">DNA microarray</span> Collection of microscopic DNA spots attached to a solid surface

A DNA microarray is a collection of microscopic DNA spots attached to a solid surface. Scientists use DNA microarrays to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. Each DNA spot contains picomoles of a specific DNA sequence, known as probes. These can be a short section of a gene or other DNA element that are used to hybridize a cDNA or cRNA sample under high-stringency conditions. Probe-target hybridization is usually detected and quantified by detection of fluorophore-, silver-, or chemiluminescence-labeled targets to determine relative abundance of nucleic acid sequences in the target. The original nucleic acid arrays were macro arrays approximately 9 cm × 12 cm and the first computerized image based analysis was published in 1981. It was invented by Patrick O. Brown. An example of its application is in SNPs arrays for polymorphisms in cardiovascular diseases, cancer, pathogens and GWAS analysis. It is also used for the identification of structural variations and the measurement of gene expression.

<span class="mw-page-title-main">Harold E. Varmus</span> American scientist (born 1939)

Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.

A respiratory pigment is a metalloprotein that serves a variety of important functions, its main being O2 transport. Other functions performed include O2 storage, CO2 transport, and transportation of substances other than respiratory gases. There are four major classifications of respiratory pigment: hemoglobin, hemocyanin, erythrocruorin–chlorocruorin, and hemerythrin. The heme-containing globin is the most commonly-occurring respiratory pigment, occurring in at least 9 different phyla of animals.

<span class="mw-page-title-main">Michael Eisen</span> American computational biologist and journal editor

Michael Bruce Eisen is an American computational biologist and the former editor-in-chief of the journal eLife. He is a professor of genetics, genomics and development at University of California, Berkeley. He is a leading advocate of open access scientific publishing and is co-founder of Public Library of Science (PLOS). In 2018, Eisen announced his candidacy U.S. Senate from California as an Independent, though he failed to qualify for the ballot.

<span class="mw-page-title-main">Joseph DeRisi</span> American biochemist

Joseph Lyman DeRisi is an American biochemist, specializing in molecular biology, parasitology, genomics, virology, and computational biology.

<span class="mw-page-title-main">Genetic analysis</span>

Genetic analysis is the overall process of studying and researching in fields of science that involve genetics and molecular biology. There are a number of applications that are developed from this research, and these are also considered parts of the process. The base system of analysis revolves around general genetics. Basic studies include identification of genes and inherited disorders. This research has been conducted for centuries on both a large-scale physical observation basis and on a more microscopic scale. Genetic analysis can be used generally to describe methods both used in and resulting from the sciences of genetics and molecular biology, or to applications resulting from this research.

<span class="mw-page-title-main">David Botstein</span> American biologist

David Botstein is an American biologist who is the chief scientific officer of Calico. He was the director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University from 2003 to 2013, where he remains an Anthony B. Evnin Professor of Genomics.

The Association of Biomolecular Resource Facilities (ABRF) is dedicated to advancing core and research biotechnology laboratories through research, communication, and education. ABRF members include over 2000 scientists representing 340 different core laboratories in 41 countries, including those in industry, government, academic and research institutions.

A gene signature or gene expression signature is a single or combined group of genes in a cell with a uniquely characteristic pattern of gene expression that occurs as a result of an altered or unaltered biological process or pathogenic medical condition. This is not to be confused with the concept of gene expression profiling. Activating pathways in a regular physiological process or a physiological response to a stimulus results in a cascade of signal transduction and interactions that elicit altered levels of gene expression, which is classified as the gene signature of that physiological process or response. The clinical applications of gene signatures breakdown into prognostic, diagnostic and predictive signatures. The phenotypes that may theoretically be defined by a gene expression signature range from those that predict the survival or prognosis of an individual with a disease, those that are used to differentiate between different subtypes of a disease, to those that predict activation of a particular pathway. Ideally, gene signatures can be used to select a group of patients for whom a particular treatment will be effective.

<span class="mw-page-title-main">History of genetic engineering</span>

Genetic engineering is the science of manipulating genetic material of an organism. The first artificial genetic modification accomplished using biotechnology was transgenesis, the process of transferring genes from one organism to another, first accomplished by Herbert Boyer and Stanley Cohen in 1973. It was the result of a series of advancements in techniques that allowed the direct modification of the genome. Important advances included the discovery of restriction enzymes and DNA ligases, the ability to design plasmids and technologies like polymerase chain reaction and sequencing. Transformation of the DNA into a host organism was accomplished with the invention of biolistics, Agrobacterium-mediated recombination and microinjection. The first genetically modified animal was a mouse created in 1974 by Rudolf Jaenisch. In 1976 the technology was commercialised, with the advent of genetically modified bacteria that produced somatostatin, followed by insulin in 1978. In 1983 an antibiotic resistant gene was inserted into tobacco, leading to the first genetically engineered plant. Advances followed that allowed scientists to manipulate and add genes to a variety of different organisms and induce a range of different effects. Plants were first commercialized with virus resistant tobacco released in China in 1992. The first genetically modified food was the Flavr Savr tomato marketed in 1994. By 2010, 29 countries had planted commercialized biotech crops. In 2000 a paper published in Science introduced golden rice, the first food developed with increased nutrient value.

Impossible Foods Inc. is a company that develops plant-based substitutes for meat products. The company's signature product, the Impossible Burger, was launched in July 2016 as a vegan alternative to beef hamburger.

References

  1. ↑ Schena, M.; Shalon, D.; Davis, R. W.; Brown, P. O. (1995). "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray". Science. 270 (5235): 467–470. Bibcode:1995Sci...270..467S. doi:10.1126/science.270.5235.467. PMID   7569999. S2CID   6720459.
  2. ↑ Eisen, M.; Spellman, P.; Brown, P.; Botstein, D. (1998). "Cluster analysis and display of genome-wide expression patterns". Proceedings of the National Academy of Sciences of the United States of America. 95 (25): 14863–14868. Bibcode:1998PNAS...9514863E. doi: 10.1073/pnas.95.25.14863 . PMC   24541 . PMID   9843981.
  3. ↑ "Impossible Foods 2015 Disruptor 50". CNBC . 2015-05-12.
  4. ↑ "Patrick O. Brown - Professor of Biochemistry, Emeritus | Welcome to Bio-X". 12 March 2014.
  5. ↑ Gitschier, Jane (2009-07-17). "You Say You Want a Revolution: An Interview with Pat Brown". PLOS Genetics. 5 (7): e1000560. doi: 10.1371/journal.pgen.1000560 . ISSN   1553-7404. PMC   2705184 . PMID   19609358.
  6. ↑ "Why we developed the microarray, Patrick Brown :: DNA Learning Center".
  7. ↑ "Patrick O. Brown".
  8. ↑ Brown, P. O. (2013). "An interview with Patrick O Brown on the origins and future of open access". BMC Biology. 11: 33–110. doi: 10.1186/1741-7007-11-33 . PMC   3626920 . PMID   23587113.
  9. 1 2 "DNA Learning Center". Archived from the original on 2017-09-21. Retrieved 2017-09-20.
  10. ↑ "The Nobel Prize in Physiology or Medicine 1989". NobelPrize.org.
  11. 1 2 3 4 "Medicine of the Midway". Spring 2005.
  12. ↑ "Stanford Medicine Magazine". Fall 2005.
  13. ↑ "The DNA Microarray". August 2005.
  14. 1 2 "Steal This Research Paper! (You Already Paid for It.)". Mother Jones. September 2013.
  15. ↑ Trevino, V.; Falciani, F.; Barrera-Saldaña, H. A. (2007-06-11). "DNA microarrays: a powerful genomic tool for biomedical and clinical research". Molecular Medicine. 13 (9–10): 527–541. doi:10.2119/2006-00107.Trevino. PMC   1933257 . PMID   17660860.
  16. ↑ "New Communication Paradigm for Science in the 21st Century". Journal of Young Investigators. May 2010. Archived from the original on 2017-09-21. Retrieved 2017-09-20.
  17. ↑ Brown, P. O. (2013-04-15). "An interview with Patrick O Brown on the origins and future of open access". BMC Biology. 11: 33. doi: 10.1186/1741-7007-11-33 . PMC   3626920 . PMID   23587113.
  18. ↑ Butler, Declan (1999-01-21). "The writing is on the web for science journals in print". Nature. 397 (6716): 195–200. Bibcode:1999Natur.397..195B. doi:10.1038/16544. PMID   9930685. S2CID   204990627.
  19. ↑ Brower, Vicki (2001-11-15). "Public library of science shifts gears". EMBO Reports. 2 (11): 972–973. doi:10.1093/embo-reports/kve239. ISSN   1469-221X. PMC   1084138 . PMID   11713184.
  20. ↑ Eisen, Michael B.; Brown, Patrick O.; Varmus, Harold E. (2002-09-12). "Public-access group supports PubMed Central". Nature. 419 (6903): 111. Bibcode:2002Natur.419..111E. doi: 10.1038/419111c . ISSN   0028-0836. PMID   12226637.
  21. ↑ "HHMI Bio". HHMI. Retrieved 7 January 2013.
  22. 1 2 3 "The Biography of a Plant-Based Burger: One man's mission to make meat obsolete". 2016-09-06.
  23. ↑ Walsh, Bryan (2013-12-16). "The Triple Whopper Environmental Impact of Global Meat Production". Time.,
  24. 1 2 Holmes, Bob (20 July 2022). "How sustainable are fake meats?". Knowable Magazine. doi: 10.1146/knowable-071922-1 . Retrieved 1 August 2022.
  25. ↑ http://dels.nas.edu/resources/static-assets/banr/AnimalProductionMaterials/ScopingWorkshopBackground.pdf Archived 2016-10-21 at the Wayback Machine [ bare URL PDF ]
  26. ↑ "Silicon Valley's Bloody Plant Burger Smells, Tastes And Sizzles Like Meat". NPR. 2016-06-21.
  27. ↑ "We tried the plant-based 'impossible burger' that's backed by Bill Gates". CNBC. 2016-08-02.
  28. ↑ "Can the meat-free Impossible Burger save the world". Sunday Times. 2017-04-19.
  29. ↑ Crews, Joel (23 April 2018). "An inside look at Impossible Foods". Food Business News.
  30. ↑ Gilchrist, Karen (7 March 2019). "How Impossible Burger's 'simple' vision won hundreds of millions in funding — and backing from Bill Gates". CNBC LLC.
  31. ↑ "David Chang Adds Plant Based 'Impossible Burger' to Nishi Menu". Eater. 2016-07-26.
  32. ↑ Rusli, Evelyn M. (7 October 2014). "The Secret of These New Veggie Burgers: Plant Blood". Wall Street Journal. WSJ. Retrieved 21 Apr 2015.
  33. ↑ Strom, Stephanie (2017-08-08). "Impossible Burger's 'Secret Sauce' Highlights Challenges of Food Tech". The New York Times. Archived from the original on 2023-10-06. Retrieved 2021-12-08.
  34. ↑ "GRN No. 737 Soy leghemoglobin preparation from a strain of Pichia pastoris". GRAS Notice Inventory. US Food and Drug Administration. 2018-07-23. Retrieved 2021-12-08.
  35. ↑ "Impossible Foods Receives No-Questions Letter from US Food and Drug Administration". Business Wire. Redwood City, CA. 2018-07-23. Retrieved 2021-12-08.
  36. ↑ Van Voris, Bob; Shanker, Deena (2021-05-03). "Impossible Foods Wins Ruling to Continue Use of Key Additive". Bloomberg. Retrieved 2021-12-08.
  37. ↑ Calma, Justine (2021-05-03). "Impossible Foods clears legal battle over the ingredient that makes its meat 'bleed'". The Verge. Retrieved 2021-12-08.
  38. ↑ Purdy, Chase (September 2018). "Functional foods are boring. Someone tell Silicon Valley". Quartzy. Retrieved 2019-05-21.
  39. ↑ Purdy, Chase (28 August 2018). "A single state wants to determine the definition of meat for America". Quartz. Retrieved 2019-05-21.
  40. ↑ Sullivan, Emily (29 August 2018). "What's Meat, Anyway? Missouri Label Law Says It Comes From An Animal; Some Disagree". NPR.org. Retrieved 2019-05-21.
  41. ↑ Purdy, Chase (29 March 2019). "The war on cauliflower rice". Quartz. Retrieved 2019-05-21.
  42. ↑ Brantley, Max (2019-03-14). "Legislature has a beef with labeling lab-grown protein as meat". Arkansas Times. Retrieved 2019-05-21.
  43. ↑ "Impossible Foods: Creating Plant-Based Alternatives to Meat | Singapore, Hong Kong, USA, Macau". United Nations Framework Convention on Climate Change Secretariat. Retrieved 3 April 2021.
  44. ↑ "NAS Award in Molecular Biology".
  45. ↑ "Takeda Award 2002 Achievements Fact Sheet" (PDF) (Press release). Takeda Foundation. Retrieved 2007-10-17.
  46. ↑ Eichler, Evan (2006). "Introductory Speech for Patrick O. Brown* * Previously presented at the annual meeting of the American Society of Human Genetics, in Salt Lake City, on October 29, 2005". The American Journal of Human Genetics. 79 (3): 427–428. doi:10.1086/500330. PMC   1559547 . PMID   16909379.
  47. ↑ "American Cancer Society to Present Highest Honor to Katie Couric, Alice T. And William H. Goodwin Jr., Mary-Claire King and Patrick O. Brown for Outstanding Contributions to Cancer Fight".
  48. ↑ "ABRF 2021 Annual Meeting". web.cvent.com.
  49. ↑ "Past Recipients". Association for Molecular Pathology. Retrieved 2023-04-12.
  50. ↑ Technology Pioneer 2016 - Patrick O Brown (Impossible Foods) (World Economic Forum)
  51. ↑ "Technology Pioneers 2016 - World Economic Forum". widgets.weforum.org.
  52. ↑ "Champions of the Earth". UNEP. Retrieved 2023-10-24.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.